The U.S. Food and Drug Administration (FDA) approved the first generic version of Copaxone in early 2015. The drug, which is known by the generic name glatiramer acetate, is approved to reduce the frequency of relapses in people with the relapsing-remitting type of multiple sclerosis. It is given as a daily injection.
- Q How soon after taking Copaxone will my symptoms improve?
- Q How does Copaxone work in treating multiple sclerosis (MS)?
- Q What should I avoid while taking Copaxone?
- Q How should I take Copaxone?
- Q What are the side effects of Copaxone?
- Q Does Copaxone interact with other medications or foods?